Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 246-253

  Nijhoff, M F ^a   Engelse, M A ^a   Dubbeld, J ^a   Braat, A E ^a   Ringers, J ^a   Roelen, D L ^a   Van Erkel, A R ^a   Spijker, H S ^a   Bouwsma, H ^a   Van Der Boog, P J M ^a   De Fijter, J W ^a   Rabelink, T J ^a   De Koning, E J P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; C PEPTIDE; CREATININE; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HEMOGLOBIN A1C; HLA ANTIGEN CLASS 2; INSULIN; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; GLUCOSE BLOOD LEVEL; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ADULT; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETIC FOOT; DISEASE DURATION; DRUG DOSE REDUCTION; FEMALE; GASTROENTERITIS; GLYCEMIC CONTROL; GRAFT RECIPIENT; HUMAN; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MALE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; THERAPY EFFECT; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FUNCTION TEST; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLUCOSE TOLERANCE TEST; GLYCEMIC INDEX; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PREDNISOLONE; PROGNOSIS; RISK FACTORS; TACROLIMUS;

EID: 84956958056     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13425     Document Type: Article

References (33)

1. Zinger A, Leibowitz G., Islet transplantation in type 1 diabetes: hype, hope and reality-A clinician's perspective. Diabetes Metab Res Rev 2014; 30: 83-87.
2. Robertson RP., Islet transplantation as a treatment for diabetes-A work in progress. N Engl J Med 2004; 350: 694-705.
3. Scharp DW, Lacy PE, Santiago JV, et al., Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51: 76-85.
4. Shapiro AM., International Trial of the Edmonton Protocol for Islet Transplantation. N Engl J Med 2006; 355: 1318-1330.
5. Barton FB, Rickels MR, Alejandro R, et al., Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436-1445.
6. Ryan AE, Paty BW, Senior PA, et al., Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
7. Shapiro AM., State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep 2011; 11: 345-354.
8. Paty BW, Harmon JS, Marsh CL, Robertson RP., Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002; 73: 353-357.
9. Chatenoud L., Chemical immunosuppression in islet transplantation-Friend or foe? N Engl J Med 2008; 358: 1192-1193.
10. Vallabhajosyula P, Hirakata A, Okumi M, Sachs DH,. Assessing the effect of immunosuppression on engraftment of pancreatic islets. Transplantation 2013; 96: 372-378.
11. Mineo D, Sageshima J, Burke GW, Ricordi C,. Minimization and withdrawal of steroids in pancreas and islet transplantation. Transpl Int 2009; 22: 20-37.
12. Bellin MD, Barton FB, Heitman A, et al., Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 2012; 12: 1576-1583.
13. Haynes R, Harden P, Judge P, et al., Alemtuzumab-based induction treatment versus basiliximab based induction treatment in kidney transplantation (the 3C Study): A randomised trial. Lancet 2014; 384: 1684-1690.
14. Tan J, Yang S, Cai J, et al., Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes 2008; 57: 2666-2671.
15. Froud T, Baidal DA, Faradji R, et al., Islet transplantation with alemtuzumab induction and calcinurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation 2008; 86: 1695-1701.
16. Ryan EA, Paty BW, Senior PA, Lakey JRT, Bigam D, Shapiro AM,. Beta-score: An assessment of beta cell function after islet transplantation. Diabetes Care 2005; 28: 343-347.
17. Matsumoto S,. Improvement of pancreatic islet cell isolation for transplantation. Proc Bayl Univ Med Cent 2007; 20: 357-362.
18. Friberg AS, Stahle M, Brandhorst H, Korsgren O, Brandhorst D,. Human islet separation utilizing a closed automated purification system. Cell Transplantation 2008; 17: 1305-1313.
19. Goto M, Eich TM, Felldin M, et al., Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture. Transplantation 2004; 78: 1367-1375.
20. Ghofaili KA, Fung M, Ao Z, et al., Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 15: 24-28.
21. Toso C, McCall M, Emamaullee J, et al., Liraglutide, a long-acting human glucagon-like peptide 1 analogue,improves human islet survival in culture. Transpl Int 2010; 23: 259-265.
22. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al., Randomized comparisons of the mixed meal tolerance test versus the glucagon stimulation test for the assessment of beta cell function in type 1 diabetes. Diabetes Care 2008; 31: 1966-1971.
23. Cantarovich D, Hodemon-Corne B, Trébern-Launay K, Giral M, Foucher Y, Dantan E,. Early steroid withdrawal compared with steroid avoidance correlated with graft failure among kidney transplant recipients with an history of diabetes. Transpl Proc 2013; 45: 1497-1502.
24. Oettl T, Zuliani E, Gaspert A, Hopfer H, Dickenmann M, Fehr T,. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: High rate of mild cellular rejection. Transplantation 2010; 89: 702-706.
25. Pascual J., Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant 2011; 16: 600-605.
26. Sandberg JO, Andersson A, Sandler S,. Exposure of rat pancreatic islets to RS-61443 inhibits beta-cell function. Transplantation 1993; 56: 1197-1201.
27. Nir T, Melton DA, Dor Y,. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553-2261.
28. van Raalte DH, Brands M, van der Zijl NJ, et al., Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: A randomised controlled trial. Diabetologia 2010; 54: 2103-2112.
29. Mazzantini M, Torre C, Miccoli M, et al., Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: A retrospective study. J Rheumatol 2012; 39: 552-557.
30. Hoes JN, van der Goes MC, van Raalte DH, et al., Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70: 1887-1894.
31. Borot S, Niclauss N, Wojtusciszyn A, et al., Impact of the number of infusion on 2-year results of islet-after-kidney transplantation in the GRAGIL Network. Transplantation 2011; 92: 1031-1038.
32. Deng S, Markmann JF, Rickels M, et al., Islet alone versus islet after kidney transplantation: Metabolic outcomes and islet graft survival. Transplantation 2009; 88: 820-825.
33. Vantyghem MC, Raverdy V, Balavoine AS, et al., Continuous glucose monitoring after islet transplantation in type 1 diabetes: An excellent graft function (beta score greater than 7) is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta score greater than 3). J Clin Endocrinol Metab 2012; 97: 2078-2083.